drugset / Trial / NCT01265615
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Phase 4
Completed
109 enrolled
Ural State Medical University
De Haar Research Foundation · collabUral Institute of Cardiology · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and phosphatemic complications alongside with great beneficial potential.
Timeline
- Start
- 2009-10
- Primary completion
- 2010-04
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcitriol | Small molecule | 2 ug | Oral |
| Comparator | Calcitriol | Small molecule | 4 ug | Oral |
| Comparator | Cholecalciferol | Other / unclassified | 1200 iu | — |
| Comparator | Cholecalciferol | Other / unclassified | 2400 iu | — |
| Comparator | Paricalcitol | Other / unclassified | 6 ug | Oral |
| Comparator | Paricalcitol | Other / unclassified | 8 ug | Oral |